Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
- Conditions
- Interventions
- First Posted Date
- 2015-12-28
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 24
- Registration Number
- NCT02639910
- Locations
- 🇬🇧
Clinical Study Site, Leeds, United Kingdom
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 133
- Registration Number
- NCT02611323
- Locations
- 🇮🇹
Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Emilia-Romagna, Italy
🇮🇹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy
🇮🇹SCDU Ematologia, Novara, Piemonte, Italy
ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)
- Conditions
- Interventions
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 37
- Registration Number
- NCT02471391
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
🇦🇺Royal Melbourne Hospital, Melbourne, Victoria, Australia
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 3100
- Registration Number
- NCT02416388
- Locations
- 🇫🇷
CH Amiens Hôpital Sud, Amiens, France
🇫🇷CHU Angers, Angers, France
🇫🇷CH Victor Dupouy, Argenteuil, France
Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)
- Conditions
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 66
- Registration Number
- NCT02401503
- Locations
- 🇩🇪
German CLL Study Group, Cologne, Germany
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Bilineal LeukemiaRefractory Acute Myeloid LeukemiaAcute Biphenotypic LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaSecondary Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaTherapy-Related Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT02397720
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 128
- Registration Number
- NCT02391480
- Locations
- 🇺🇸
City of Hope /ID# 154053, Duarte, California, United States
🇺🇸UC Davis Comp Cancer Ctr /ID# 154644, Sacramento, California, United States
🇺🇸Indiana Univ School Medicine /ID# 132946, Indianapolis, Indiana, United States
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
- Conditions
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 69
- Registration Number
- NCT02296918
- Locations
- 🇺🇸
Research Site, Columbus, Ohio, United States
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 94
- Registration Number
- NCT02287233
- Locations
- 🇺🇸
Univ Kansas Med Ctr /ID# 131175, Kansas City, Kansas, United States
🇺🇸Vanderbilt University Medical Center /ID# 131177, Nashville, Tennessee, United States
🇺🇸Weill Cornell Medical College /ID# 131170, New York, New York, United States
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 38
- Registration Number
- NCT02265731
- Locations
- 🇯🇵
Nagoya City University Hospital /ID# 129278, Nagoya shi, Aichi, Japan
🇯🇵NHO Nagoya Medical Center /ID# 129222, Nagoya-shi, Aichi, Japan
🇯🇵Osaka University Hospital /ID# 169862, Suita-shi, Osaka, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.